文献速递流行病学与生物统计基础与转化研究

代谢减重手术与成人长期生存的关联:174772例匹配队列与前瞻性对照研究的一阶段荟萃分析

Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants.
PubMed 文献 · Lancet · 2021-05-06

该研究采用一阶段荟萃分析,整合16项匹配队列研究和1项前瞻性对照试验的个体生存数据,比较代谢减重手术与常规管理对重度肥胖患者全因死亡的影响。

核心结论

  • 代谢减重手术与肥胖成人全因死亡率显著降低及预期寿命延长相关,且糖尿病患者的生存获益更为明显。

研究设计与样本

  • 预设的一阶段荟萃分析,整合来自16项匹配队列研究和1项前瞻性对照试验的个体生存数据。
  • 检索PubMed、Scopus和MEDLINE至2021年2月3日,纳入比较代谢减重手术与非手术管理的随机试验、前瞻性对照研究和匹配队列研究。
  • 采用共享脆弱性(随机效应)和分层Cox模型比较全因死亡率,并计算需治疗人数及外推预期寿命。

临床怎么用

  • 对于重度肥胖成人,代谢减重手术可显著降低长期全因死亡风险并延长预期寿命,尤其适用于合并糖尿病的患者。
  • 临床决策时应结合糖尿病状态评估手术的生存获益,糖尿病患者手术获益更大,需治疗人数更低。
  • 胃旁路术、束带术和袖状胃切除术在生存获益上未见显著差异,术式选择可综合考虑其他因素。

局限性

  • 研究基于观察性匹配队列和少量前瞻性对照试验,可能存在残余混杂。
  • 未报告随机对照试验的长期死亡率数据,因果推断需谨慎。
  • 原文未报告纳入研究的详细偏倚风险评估及异质性来源分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic-bariatric surgery delivers substantial weight loss and can induce remission or improvement of obesity-related risks and complications. However, more robust estimates of its effect on long-term mortality and life expectancy-especially stratified by pre-existing diabetes status-are needed to guide policy and facilitate patient counselling. We compared long-term survival outcomes of severely obese patients who received metabolic-bariatric surgery versus usual care. METHODS: We did a prespecified one-stage meta-analysis using patient-level survival data reconstructed from prospective controlled trials and high-quality matched cohort studies. We searched PubMed, Scopus, and MEDLINE (via Ovid) for randomised trials, prospective controlled studies, and matched cohort studies comparing all-cause mortality after metabolic-bariatric surgery versus non-surgical management of obesity published between inception and Feb 3, 2021. We also searched grey literature by reviewing bibliographies of included studies as well as review articles. Shared-frailty (ie, random-effects) and stratified Cox models were fitted to compare all-cause mortality of adults with obesity who underwent metabolic-bariatric surgery compared with matched controls who received usual care, taking into account clustering of participants at the study level. We also computed numbers needed to treat, and extrapolated life expectancy using Gompertz proportional-hazards modelling. The study protocol is prospectively registered on PROSPERO, number CRD42020218472. FINDINGS: Among 1470 articles identified, 16 matched cohort studies and one prospective controlled trial were included in the analysis. 7712 deaths occurred during 1·2 million patient-years. In the overall population consisting 174 772 participants, metabolic-bariatric surgery was associated with a reduction in hazard rate of death of 49·2% (95% CI 46·3-51·9, p<0·0001) and median life expectancy was 6·1 years (95% CI 5·2-6·9) longer than usual care. In subgroup analyses, both individuals with (hazard ratio 0·409, 95% CI 0·370-0·453, p<0·0001) or without (0·704, 0·588-0·843, p<0·0001) baseline diabetes who underwent metabolic-bariatric surgery had lower rates of all-cause mortality, but the treatment effect was considerably greater for those with diabetes (between-subgroup I2 95·7%, p<0·0001). Median life expectancy was 9·3 years (95% CI 7·1-11·8) longer for patients with diabetes in the surgery group than the non-surgical group, whereas the life expectancy gain was 5·1 years (2·0-9·3) for patients without diabetes. The numbers needed to treat to prevent one additional death over a 10-year time frame were 8·4 (95% CI 7·8-9·1) for adults with diabetes and 29·8 (21·2-56·8) for those without diabetes. Treatment effects did not appear to differ between gastric bypass, banding, and sleeve gastrectomy (I2 3·4%, p=0·36). By leveraging the results of this meta-analysis and other published data, we estimated that every 1·0% increase in metabolic-bariatric surgery utilisation rates among the global pool of metabolic-bariatric candidates with and without diabetes could yield 5·1 million and 6·6 million potential life-years, respectively. INTERPRETATION: Among adults with obesity, metabolic-bariatric surgery is associated with substantially lower all-cause mortality rates and longer life expectancy than usual obesity management. Survival benefits are much more pronounced for people with pre-existing diabetes than those without. FUNDING: None.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Syn NL, Cummings DE, Wang LZ, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet. 2021. PMID: 33965067. doi:10.1016/S0140-6736(21)00591-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。